|
|
|
| Effect of Jiaomu Gualou Decoction in the Treatment of Chronic Heart Failure and Its Influence on Myocardial Microcirculation |
| SHAN Shixi |
| First-author's address: Tai’an Second Hospital of Traditional Chinese Medicine, Shandong Province, Tai’an 271000, China |
|
|
|
|
Abstract Objective: To investigate the effect of Jiaomu Gualou Decoction in the treatment of chronic heart failure and its influence on myocardial microcirculation. Method: This study was conducted from November 2019 to November 2022. 92 patients with chronic heart failure treated in Tai’an Second Hospital of Traditional Chinese Medicine during this period were selected and divided into a control group (n=46, treated with conventional western medicine) and a study group (n=46, treated with conventional western medicine combined with Jiaomu Gualou Decoction) by applying the random number table method. The TCM symptoms scores (shortness of breath, phlegm, chest and rib swelling, fatigue), cardiac function indexes [left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD)], inflammatory factors [interleukin-8 (IL-8), interleukin-17 (IL-17), hypersensitive C reactive protein (hs-CRP )], myocardial microcirculatory indexes (ST-segment drop frequency, duration, total myocardial ischemic load) and oxidative stress indexes [lipid peroxidation (LPO), superoxide dismutase (SOD), malondialdehyde (MDA), glutathione peroxidase (GSH-Px)]. Result: Before treatment, there were no significant differences in the scores of shortness of breath, phlegm, chest and rib swelling and fatigue between the two groups (P>0.05). After treatment, the scores of shortness of breath, phlegm, chest and rib swelling, and fatigue decreased in both groups, and those in the study group were lower than those in the control group (P<0.05). Before treatment, there were no significant differences in LVEF, LVESD and LVEDD between the two groups (P>0.05). After treatment, LVEF increased, LVESD and LVEDD decreased in both groups, and LVEF in the study group was higher than that in the control group, LVESD and LVEDD in the study group were lower than those in the control group (P<0.05). Before treatment, there were no significant differences in the levels of IL-8, IL-17 and hs-CRP between the two groups (P>0.05). After treatment, the levels of IL-8, IL-17 and hs-CRP decreased in both groups, and those in the study group were lower than those in the control group (P<0.05). Before treatment, there were no significant differences in the frequency, duration and total myocardial ischemia load of ST-segment between the two groups (P>0.05). After treatment, the frequency, duration and total myocardial ischemia load of ST-segment decreased in both groups, and those in the study group were lower than those in the control group (P<0.05). Before treatment, there were no significant differences in LPO, SOD, MDA and GSH-Px between the two groups (P>0.05). After treatment, the levels of GSH-Px and SOD increased, LPO and MDA decreased in both groups, and the levels of GSH-Px and SOD in the study group were higher than those in the control group, and the levels of LPO and MDA were lower than those in the control group (P<0.05). Conclusion: Treatment of patients with chronic heart failure with Jiaomu Gualou Decoction can improve patients' cardiac function, myocardial microcirculation and reduce the degree of inflammatory response and oxidative stress.
|
|
Received: 14 April 2023
|
|
|
|
|
|
|
